OncoCyte (NASDAQ:OCX) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX) in a note issued to investors on Thursday. The firm set a “sell” rating on the stock.

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $4.25 price target on shares of OncoCyte in a report on Wednesday, November 13th.

OncoCyte Stock Down 0.9 %

Shares of OncoCyte stock opened at $2.11 on Thursday. The company has a 50-day simple moving average of $2.64 and a two-hundred day simple moving average of $2.90. OncoCyte has a 52-week low of $1.97 and a 52-week high of $3.82.

OncoCyte (NASDAQ:OCX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.54). The firm had revenue of $0.12 million for the quarter. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%. During the same period in the prior year, the business earned ($0.57) earnings per share. As a group, analysts anticipate that OncoCyte will post -2.57 earnings per share for the current fiscal year.

Insider Activity at OncoCyte

In other news, CFO Andrea S. James bought 33,670 shares of the company’s stock in a transaction on Wednesday, October 2nd. The shares were acquired at an average cost of $2.97 per share, with a total value of $99,999.90. Following the completion of the transaction, the chief financial officer now owns 33,670 shares of the company’s stock, valued at approximately $99,999.90. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Broadwood Partners, L.P. purchased 1,315,339 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were purchased at an average price of $2.95 per share, with a total value of $3,880,250.05. Following the completion of the purchase, the insider now owns 6,244,405 shares in the company, valued at approximately $18,420,994.75. This trade represents a 26.69 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 1,381,509 shares of company stock worth $4,052,425 over the last quarter. Company insiders own 1.58% of the company’s stock.

Institutional Trading of OncoCyte

An institutional investor recently raised its position in OncoCyte stock. Geode Capital Management LLC raised its stake in shares of OncoCyte Co. (NASDAQ:OCX) by 12.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 103,980 shares of the company’s stock after purchasing an additional 11,289 shares during the period. Geode Capital Management LLC owned 0.62% of OncoCyte worth $296,000 as of its most recent SEC filing. 55.35% of the stock is owned by institutional investors and hedge funds.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.